



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/315,292	05/20/1999	CLARENCE FRANK BENNETT	ISIS-3561	6344
34138	7590	10/25/2006		
ISIS PHARMACEUTICALS, INC 1896 RUTHERFORD ROAD CARLBAD, CA 92008			EXAMINER BOWMAN, AMY HUDSON	
			ART UNIT 1635	PAPER NUMBER
DATE MAILED: 10/25/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No. 09/315,292	Applicant(s) BENNETT ET AL.	
	Examiner Amy H. Bowman	Art Unit 1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 10 August 2006.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 66, 70-75 and 78-82 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 66, 70-75 and 78-82 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Status of Application/Amendment/Claims***

Applicant's response filed 8/10/2006 has been considered. Rejections and/or objections not reiterated from the previous office action mailed 5/10/2006 are hereby withdrawn. The following rejections and/or objections are either newly applied or are reiterated and are the only rejections and/or objections presently applied to the instant application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Applicant has added claims 78-82. Therefore, claims 66, 70-75 and 78-82 are pending in the application.

### ***Response to Arguments--Claim Rejections - 35 USC § 103(a)***

Claims 66 and 70-75 stand rejected under 35 U.S.C. 103(a), as being unpatentable over Kole et al. (U.S. 5,627,274), in view of Nyce et al. (WO 96/40266) and Nicklin et al. (WO 98/09633), for the reasons of record set forth in the office action mailed 5/10/2006.

Applicant has cancelled claims 67-69, obviating the rejection against these claims.

Applicant asserts that Kole teaches oligonucleotides to redirect splicing, not to degrade target mRNAs, as taught by Nyce and Nicklin. Applicant concludes that one making oligonucleotides that do not promote RNase H cleavage would not look to a

Art Unit: 1635

reference that teaches oligonucleotides that promote RNase H cleavage to determine what chemical modifications to use. Contrary to applicant's assertion, Kole, Nyce, and Nicklin each teach modified antisense oligonucleotides. Regardless of the fact that Kole teaches such oligonucleotides to redirect splicing, one would still incorporate the instantly recited chemical modifications into the antisense oligonucleotides of Kole because the modifications were known in the art to enhance the resistance of antisense oligonucleotides to nucleases. Furthermore, Kole et al. teaches 2'-O-methyl modifications, which further demonstrates that Kole recognized the value of 2'-modifications, despite the alleged difference in mechanism. This is because 2'-modifications were known to enhance the activity of antisense oligonucleotides.

Applicant further asserts that Nicklin teaches a long series of 2'-modifications and that there is no motivation to select the specific 2'-modification now claimed. The list of chemical modifications taught by Nicklin et al. are all alleged by Nicklin to be useful to enhance oligonucleotide activity, all of which are preferred because they enhance activity. Specifically, 2'-O-methoxyethyl is a modification that was known in the art to enhance activity, as evidenced by Nicklin. One would have been motivated to incorporate such a modification into the antisense oligonucleotides of Kole and would reasonably expect for the modification to benefit stability of the oligonucleotides of Kole.

Furthermore, as evidenced by the 35 U.S.C. 103(a) rejection below, the invention of the above claims is considered obvious even in absence of the Kole et al. reference.

***New Rejections***

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 66, 70-75 and 78-82 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nyce et al. (WO 96/40266), in view of Nicklin et al. (WO 98/09633).

The invention of the above claims is drawn to a method of administering an oligonucleotide into the lung of a mammal, comprising aerosolizing the oligonucleotide wherein the aerosol particles have a size of about 1 to about 5 microns, and introducing the aerosolized oligonucleotide into the lung of the mammal, wherein the sugar moiety of at least one nucleoside unit is a 2'-O-methoxyethyl, and the oligonucleotide is taken up by at least one cell type in the lung. The oligonucleotide is in an aqueous media such as sterilized, pyrogen free water or saline solution or in a saline solution or a powder. The invention is further drawn to a method of increasing uptake into lung cells of a phosphorothioate containing oligonucleotide delivered by pulmonary administration into lung cells comprising incorporation of a 2'-O-methoxyethyl modification into the oligonucleotide.

Nyce et al. teach that respirable antisense oligonucleotides can be formulated to be liquid or solid (see page 10). Liquid compositions comprise the antisense compound and sterile, pyrogen free water or saline solution (see page 9, for example). Nyce et al.

Art Unit: 1635

teach that suitable formulations for delivery include powders (see page 12). Nyce et al. teach that respirable antisense oligonucleotides can be formulated into powders and effectively delivered with a metered dose inhaler. Nyce et al. teach methylphosphonate and phosphorothioate linkages to render respirable antisense oligonucleotides more stable *in vivo* (see page 7).

Nyce et al. teach that particles comprised of antisense compound should be of respirable size that is particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. Nyce et al. teach that in general, particles ranging from about .5 to 10 microns in size are respirable (see page 10). Therefore, Nyce et al. teach respirable particles "about 1 to about 5 microns", as instantly recited.

Nyce et al. teach a method of administering the aerosolized antisense oligonucleotides to animals *in vivo* (see page 16, for example) and teach uptake of the oligonucleotide in the lungs.

Nyce et al. do not teach 2'-O-methoxyethyl modifications.

Nicklin et al. teach antisense oligonucleotides and teach that modification of antisense oligonucleotides confers increased nuclease resistance, increased uptake into cells, and increased binding affinity for the RNA target (see page 2). Nicklin et al. teach 2' modifications including 2'-alkoxyalkoxy, 2'-O-methoxyethyl, and 2'-O-dialkylaminoalkoxy modifications. Nicklin et al. teach phosphorothioate, methylphosphonate, and non-phosphorous containing linkage modifications (see pages 4 and 5).

It would have been obvious to incorporate 2'-O-methoxyethyl modifications, as taught by Nicklin et al. into the antisense oligonucleotides taught by Nyce et al.

One would have been motivated to incorporate 2'-O-methoxyethyl modifications because Nicklin et al. teach that such modifications confer increased nuclease resistance, increased uptake into cells, and increased binding affinity for the RNA target. Since Nyce et al. teach other modifications, such as incorporation of phosphorothioates, in order to render the respirable antisense oligonucleotides more stable *in vivo*, one would have been motivated to incorporate 2'-O-methoxyethyl modifications as well since they were also known in the art to enhance oligonucleotide activity, as evidenced by Nicklin et al.

Finally, one would have a reasonable expectation of success to that the chemical modifications taught by Nicklin et al. would benefit the antisense oligonucleotides of Nyce et al. because each of the instantly recited modifications were known in the art at the time the invention was made to enhance the activity of antisense oligonucleotides, as evidenced by Nicklin et al. and Nyce et al.

Thus in the absence of evidence to the contrary, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

### **Conclusion**

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP

§ 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy H. Bowman whose telephone number is 571-272-0755.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image




Art Unit: 1635

problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Amy H. Bowman  
Examiner  
Art Unit 1635

JAMES SCHULTZ, PH.D.  
PRIMARY EXAMINER

A handwritten signature in black ink, appearing to read "J. Schultz", is written over the printed name of the primary examiner.